Coronavirus Update

FDA Authorizes First Covid-19 and Flu Combination Test for Use with Home-Collected Samples

The U.S. Food and Drug Administration authorized the first diagnostic test for at home collection of patient samples to detect both Covid-19 and influenza A and B (flu).

The FDA authorized Quest Diagnostics RC Covid-19 +Flu RT-PCR Test for prescription use with the Quest Diagnostics Self-Collection Kit for Covid-19 +Flu by individuals who are suspected of respiratory viral infection consistent with Covid-19 when home collection is determined to be appropriate by an individual’s healthcare provider. Under a health care provider’s order, patients can collect a sample at home and ship it to a Quest Diagnostics laboratory for analysis following the instructions included with the self-collection kit.

More details on the FDA website.

06.12.2020

Read all latest stories

Related articles

Photo

Precise, affordable, and portable

A health testing platform that consolidates multimodal and multiplex testing to one device

Fluxergy envisions that a fully articulated democratized testing health system has the potential to reduce the likelihood and the ultimate severity of pandemics like Covid-19. Our mission is to…

Photo

1-Hour-RT-PCR

Detect SARS-CoV-2 on the Fluxergy Platform

Now Available: The Fluxergy Analyzer System is a testing platform designed for sample-to-answer point-of-care testing, enabling clinicians to cost-effectively conduct molecular in vitro diagnostic…

Photo

SARS-CoV-2 detection and sequencing

'Nirvana': Fast, portable test diagnoses Covid-19, tracks variants

Clinicians using a new viral screening test can not only diagnose Covid-19 in a matter of minutes with a portable, pocket-sized machine, but can also simultaneously test for other viruses—like…

Related products

Subscribe to Newsletter